Stockscreener 앱 받기
52.73
0.30%
-0.16
시간 외 거래:
52.55
-0.18
-0.34%
전일 마감가:
$52.89
열려 있는:
$52.874
하루 거래량:
1.40M
Relative Volume:
0.65
시가총액:
$8.79B
수익:
$1.56B
순이익/손실:
$152.72M
주가수익비율:
58.63
EPS:
0.8994
순현금흐름:
$221.80M
1주 성능:
+1.95%
1개월 성능:
-4.27%
6개월 성능:
+57.31%
1년 성능:
+101.80%
1일 변동 폭
$52.48
$53.84
1주일 범위
$51.25
$53.88
52주 변동 폭
$25.16
$55.67
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, HLN, TEVA, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
52.73 | 8.82B | 1.56B | 152.72M | 221.80M | 0.8994 |
TAK
Takeda Pharmaceutical Co Adr
|
17.44 | 55.06B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.94 | 43.07B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.08 | 35.88B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
76.92 | 31.59B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
527.94 | 26.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-29 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2025-11-11 | 개시 | Truist | Buy |
| 2025-09-26 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | 개시 | Wells Fargo | Overweight |
| 2025-07-15 | 개시 | Goldman | Buy |
| 2025-06-17 | 업그레이드 | UBS | Neutral → Buy |
| 2025-05-28 | 개시 | Needham | Buy |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | 업그레이드 | UBS | Sell → Neutral |
| 2025-02-11 | 개시 | Deutsche Bank | Buy |
| 2024-11-05 | 업그레이드 | Stifel | Hold → Buy |
| 2024-06-17 | 개시 | TD Cowen | Buy |
| 2024-03-19 | 개시 | Robert W. Baird | Outperform |
| 2024-02-20 | 다운그레이드 | UBS | Neutral → Sell |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Alkermes set to report earnings amid orexin frenzy and M&A buzz - Investing.com
Alkermes Plc (ALKS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Alkermes Plc (ALKS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Alkermes plc (8AK) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (8AK) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
What Does the Recent Insider Sale by Alkermes' VP of Finance Signify - Kavout | AI
Alkermes plc (ALKS) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Interim Analysis: Sustained Wakefulness with Alixorexton in Narcolepsy - Sleep Review
Alkermes plc (ALKS) Q4 2023 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes Plc (ALKS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Alkermes plc (ALKS) Q3 2023 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Alkermes plc (ALKS) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Stifel raises Alkermes stock price target on orexin program outlook By Investing.com - Investing.com South Africa
Stifel raises Alkermes stock price target on orexin program outlook - Investing.com
ALKS Upgraded by Stifel -- Price Target Raised to $63 - GuruFocus
(ALKS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Sustained Alixorexton Narcolepsy Data Could Be A Game Changer For Alkermes (ALKS) - simplywall.st
Alkermes to Report Second Quarter Financial Results on July 28, 2026 - Moomoo
Press Release: Alkermes to Report Second Quarter Financial Results on July 28, 2026 - Moomoo
Narcolepsy Treatments Are Advancing. Can Access? - Sleep Review
Alkermes Says Lead Drug Maintains Wakefulness Benefits in Long-Term Narcolepsy Study - Sahm
ALKS Maintained by Needham -- Price Target Raised to $62.00 - GuruFocus
TD Cowen raises Alkermes stock price target to $57 on drug data - Investing.com UK
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis - BioSpace
Alkermes releases nine-month data as OX2R race heats up - Clinical Trials Arena
Alkermes reports alixorexton narcolepsy trial data - grafa.com
What's Going on With Alkermes Stock Monday?Alkermes (NASDAQ:ALKS) - Benzinga
TD Cowen raises Alkermes stock price target to $57 on drug data By Investing.com - Investing.com South Africa
Alkermes (ALKS) Reports Positive Interim Results for Alixorexton in Narcolepsy Trials - GuruFocus
Alkermes reports nine-month narcolepsy drug trial results By Investing.com - Investing.com South Africa
JPMorgan Resumes Coverage of Alkermes (ALKS) with Neutral Rating - GuruFocus
ALKS Reinstated by JP Morgan -- Price Target Set at $60 - GuruFocus
Alkermes reports nine-month narcolepsy drug trial results - Investing.com
JPMorgan resumes Alkermes stock coverage with neutral rating By Investing.com - Investing.com Australia
JPMorgan resumes Alkermes stock coverage with neutral rating - Investing.com
Alkermes PLC (ALKS) Stock Down 3.4% but Still Overvalued -- GF S - GuruFocus
Alkermes PLC (ALKS) Stock Down 3.4% but Still Overvalued -- GF Score: 64/100 - GuruFocus
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.17%
2.01%
자본화:
|
볼륨(24시간):